SCHEMBL2146755

SCHEMBL2146755

Cc1noc(C)c1-c1c(C=NO)c2ccc(Cl)cc2n1-c1ccc(O)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 8/20 0.36
MAT2A P31153 3/20 0.34
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP2 O95551 1/20 0.33
ERN1 O75460 3/20 0.33
PLK4 O00444 1/20 0.32
AURKA O14965 1/20 0.32
PDPK1 O15530 1/20 0.32
ROCK2 O75116 1/20 0.32
EGFR P00533 1/20 0.32
PRKCG P05129 1/20 0.32
INSR P06213 1/20 0.32
LCK P06239 1/20 0.32
CDK1 P06493 1/20 0.32
CSF1R P07333 1/20 0.32
LYN P07948 1/20 0.32
PIM1 P11309 1/20 0.32
FGFR1 P11362 1/20 0.32
PRKACA P17612 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2146748 1.00 BRD4 (0.36) BRD4MAT2AKMT2ANPSR1TDP2
SCHEMBL2146546 0.88 PIK3CD (0.37) BRD4KMT2ANPSR1ERN1SMN1; SMN2
SCHEMBL2146543 0.88 PIK3CD (0.37) BRD4KMT2ANPSR1ERN1SMN1; SMN2
SCHEMBL2146930 0.86 ESR2 (0.39) BRD4KMT2AKDM4ELMNAMAPT
SCHEMBL2146933 0.86 ESR2 (0.39) BRD4KMT2AKDM4ELMNAMAPT
SCHEMBL2146513 0.86 MLYCD (0.34) BRD4MAT2AERN1KDM4ELMNA
SCHEMBL2146509 0.86 MLYCD (0.34) BRD4MAT2AERN1KDM4ELMNA
SCHEMBL2146304 0.85 ERN1 (0.36) BRD4KMT2AERN1LMNA
SCHEMBL2146302 0.85 ERN1 (0.36) BRD4KMT2AERN1LMNA
SCHEMBL2146838 0.82 PTGDR2 (0.39) BRD4KMT2AERN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102216268-A Novel estrogen receptor ligands KAROBIO AB 2011-10-12 CN claimed
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US claimed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP claimed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO claimed
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US disclosed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP disclosed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, ESRRA, GPER1 BRD4 891/4885MAT2A 3916/4885KMT2A 1814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.